Needham cuts Artiva Biotherapeutics to hold from buy
ARTV•Needham cut its rating on Artiva Biotherapeutics to hold from buy.
Related News
Meta’s $25 billion stock sale reportedly ended five times oversubscribed
META•
Oncolytics says pelareorep shows durable survival benefit in anal cancer
ONCY•
Trinseo adjourns annual shareholder meeting to November 20, 2026
TSE•
AI's price war could be a win for hyperscalers, Citadel says
QQQ•
Clean Energy supplies renewable natural gas for PTI fleet serving Graphic Packaging
CLNE•